Results 1 to 10 of about 4,976,582 (419)
Nature Reviews Disease Primers, 2020 Bladder cancer is a highly prevalent disease and is associated with substantial morbidity, mortality and cost. Environmental or occupational exposures to carcinogens, especially tobacco, are the main risk factors for bladder cancer. Most bladder cancers are diagnosed after patients present with macroscopic haematuria, and cases are confirmed after ...
Oner Sanli +6 more
semanticscholar +3 more sources
Treatment of muscle‐invasive and advanced bladder cancer in 2020
Ca-A Cancer Journal for Clinicians, 2020 Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades, the systemic management of muscle‐invasive and advanced bladder cancer has primarily consisted of platinum‐based chemotherapy.
Vaibhav G Patel +2 more
exaly +2 more sources
The role of the HIF‐1α/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer
Cancer Communications, 2021 As a rate‐limiting enzyme of glycolysis, pyruvate kinase muscle isozyme M2 (PKM2) participates in tumor metabolism and growth. The regulatory network of PKM2 in cancer is complex and has not been fully studied in bladder cancer. The 5‐methylcytidine (m5C)
Qiang Lu, Ji-fu Wei, Haiwei Yang
exaly +2 more sources
Epidemiology of Bladder Cancer [PDF]
Medical Sciences, 2020 Based on the latest GLOBOCAN data, bladder cancer accounts for 3% of global cancer diagnoses and is especially prevalent in the developed world. In the United States, bladder cancer is the sixth most incident neoplasm.
Kalyan Saginala +5 more
semanticscholar +4 more sources
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
Cell, 2017 A Gordon Robertson +2 more
exaly +2 more sources
Current Treatment Options in Oncology, 2009 Bladder cancer is a complex disease of older patients with coexisting medical problems requiring multimodal therapy. For patients with localized bladder cancer, standard management for superficial disease includes transurethral resection with or without intravesical therapy, while muscle-invasive cancer is managed with neoadjuvant cisplatin- based ...
David J. Gallagher, Matthew I. Milowsky
+10 more sources
The Scientific World JOURNAL, 2011 To review the epidemiology, diagnosis, and management of all stages of bladder cancer with an emphasis on studies published within the last year.Smoking continues to be the most important risk factor for the development of bladder cancer, and this risk has increased over time.
Todd M, Morgan +2 more
openaire +5 more sources
Frontiers in Surgery, 2022 IntroductionNon-muscle-invasive bladder cancer (NMIBC) is a common and heterogeneous disease; many patients develop recurrent or progress to muscle-invasive disease.
Kelly Ward +4 more
doaj +1 more source
Genome Medicine, 2022 Background Three-quarters of bladder cancer patients present with early-stage disease (non-muscle-invasive bladder cancer, NMIBC, UICC TNM stages Ta, T1 and Tis); however, most next-generation sequencing studies to date have concentrated on later-stage ...
Anshita Goel +16 more
doaj +1 more source
PD-L2 Is Constitutively Expressed in Normal and Malignant Urothelium
Frontiers in Oncology, 2021 The use of immune checkpoint blockade, in particular PD-1 and PD-L1 inhibitors, is now commonplace in many clinical settings including the treatment of muscle-invasive bladder cancer (MIBC).
Alexander C. Dowell +9 more
doaj +1 more source